ClinicalTrials.gg
Not yet recruitingNCT07760077Updated Aug 12, 2026

Phase I Study of QLS1510 Tablets in Healthy Participants

A Phase 1 interventional study of QLS1510 Tablets and QLS1510 placebo Tablets in Inflammatory Bowel Disease (IBD), sponsored by Shanghai Qilu Pharmaceutical Research and Development Center LTD. Not yet recruiting. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Shanghai Qilu Pharmaceutical Research and Development Center LTD (part of Qilu Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QLS1510 in Healthy participants

02

Conditions studied

  • Inflammatory Bowel Disease (IBD)
03

In context

Inflammatory Bowel Diseases

1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 426 are open to participants now.

This study's planned enrollment of 90 is above the median of 68 across 870 interventional studies indexed under Inflammatory Bowel Diseases.

Browse Inflammatory Bowel Diseases studies →

Lead sponsor

Shanghai Qilu Pharmaceutical Research and Development Center LTD is the lead sponsor of 7 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Male and female adults aged between 18 and 45 years, inclusive, at the time of ,
  2. Medically healthy with no or relevant abnormalities in medical history, physical exam, vital signs, , or laboratory evaluations as assessed by the Investigator,
  3. Body weight ≥50 kg for males and ≥45 kg for females with a (BMI) between 18.0 and 26.0 kg/m2,
  4. Participants (including their partners) confirm they have no plans to donate sperm or egg, undergo in vitro fertilization (IVF), or become pregnant, and they agree to use highly effective methods.
  5. Understand and comply with the study procedures and methods, voluntarily participate in the trial, and provide written informed consent.

Key Exclusion Criteria:

  1. Participants with any disease identified at screening that warrants exclusion in the Investigator's judgment,
  2. Participants with a history of severe allergic reactions (e.g., angioedema or anaphylactic shock), atopic diathesis (e.g., pollen allergy, allergy to two or more drugs or foods), and/or known to the IP or any of its components,
  3. Participants with functional asplenia, history of splenectomy, or prior exposure to therapies or agents, or any other condition that, in the investigator's judgment, compromises immune function,
  4. Participants with positive test results for surface antigen (HBsAg), or positive hepatitis B core antibody (HBcAb) and detectable hepatitis B virus deoxyribonucleic acid (HBV-DNA), or positive virus antibody (HCVAb), Treponema pallidum-specific antibody, or (HIV) antibody during the screening period,
  5. Participants with a 12-lead ECG at screening/baseline showing (QT corrected per Fridericia's formula) > 450 msec for males and > 470 msec for females,
  6. Participants with supine systolic blood pressure ≥140 mmHg or \<90 mmHg or diastolic blood pressure ≥90 mmHg or \<60 mmHg after resting in the supine position for at least 5 minutes at screening/baseline,
  7. Participants with pulse or heart rate (HR) > 100 or \< 50 bpm after at least 5 minutes of rest at screening/baseline,
  8. Participants with any of the following laboratory abnormalities at screening/baseline:

    1. or AST > (ULN);
    2. Total > 1.5 ULN (direct bilirubin can be measured in participants with a history of Gilbert's syndrome, and participants can be enrolled into this study if direct bilirubin ≤ ULN),
  9. Participants with an estimated (eGFR) \< 90 mL/min/1.73 m² at screening/baseline, calculated using the Modification of Diet in Renal Disease (MDRD) formula,
  10. Participants with a serious infection (e.g., requiring hospitalization, systemic antibacterial therapy, or opportunistic infections) within 6 months prior to screening, or with a history of chronic or recurrent infectious disease that, in the opinion of the investigator, may preclude safe study participation,
  11. Participants who have received a live (attenuated) vaccine within 6 weeks prior to the first dose of IP, or who plan to receive a live (attenuated) vaccine during the study period or within 8 weeks after the last dose of IP,
  12. Participants who have participated in clinical trials of another product,
  13. Participants who have experienced major trauma,
  14. Participants with an acute illness (e.g., nausea, vomiting, fever, or diarrhea) within 1 week prior to the first dose of IP,
  15. Pregnant or breastfeeding women or participants with a positive pregnancy test result,
  16. Participants who, in the investigator's judgment, may be at increased risk of study-related complications, may interfere with the interpretation of study results, or are otherwise unsuitable for study participation.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Single ascending doses of QLS1510 tablet

    Drug: QLS1510 Tablets

  • Experimental
    Multiple ascending doses of QLS1510 tablet

    Drug: QLS1510 Tablets

  • Placebo comparator
    Single ascending doses of placebo

    Drug: QLS1510 placebo Tablets

  • Placebo comparator
    Multiple ascending doses of placebo

    Drug: QLS1510 placebo Tablets

Interventions

  • DrugQLS1510 Tablets

    Oral (swallow)

  • DrugQLS1510 placebo Tablets

    Oral (swallow)

06

What researchers measure

Primary outcomes

  1. Number of Participants with treatment-emergent adverse events (TEAEs)

    Time frame: Up to Week 4

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Jan 2027, 5 months later.

Of 35 industry-sponsored phase 1 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's planned 5 months is below that.

Counting every sponsor, half of 51 studies reached it within 12 months; a quarter within 4 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2026
First posted
Aug 12, 2026
StartEst.
Aug 30, 2026
Primary completionEst.
Jan 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07760077
Responsible party
Sponsor
First posted
Aug 12, 2026
Start date
Aug 30, 2026 (estimated)
Primary completion
Jan 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Aug 12, 2026

Study contacts

Peiying Li, PhD
Contact
peiyingli.md@gmail.com
15800616866

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion